Skip to main content
OpenTrials
Completed

NCT Number: NCT05148312

Single-dose AQ001S PK Study in Healthy Volunteers

This is a randomized, open label, single-center, single-dose, four-period crossover clinical study to assess the pharmacokinetic profile and safety of a budesonide inhalation solution (AQ001S) compared to a budesonide inhalation suspension (comparator) in healthy volunteers.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pharmacokinetics

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

MC Comac Medical Ltd.

Sofia, 1612, Bulgaria

About this study

This is a randomized, open label, single-center, single-dose, four-period crossover clinical study to assess the pharmacokinetic profile and safety of a budesonide inhalation solution (AQ001S) compared to a budesonide inhalation suspension (comparator) in healthy volunteers. Three (3) different AQ001S concentrations (i.e. 0.125 mg/2 mL, 0.250 mg/2mL and 0.500 mg/2 mL) will be compared to budesonide inhalation suspension 1.0 mg/2 ml.

Twenty (20) male and female healthy volunteers, from 18 to 60 years old, must complete the study. The study drug will be administered by nebulization.

The primary PK objective is to characterize the pharmacokinetic (PK) profile of AQ001S inhalation solution.

The primary safety objective is to assess the safety of AQ001S inhalation solution.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects who have given written informed consent.
  • Healthy volunteers of both genders, aged ≥ 18 and ≤ 60 years.
  • Subjects with body weight > 45 kg and Body Mass Index ≥ 18.5 and ≤ 24.9kg/m2.
  • Healthy volunteers are declared healthy based on medical history, physical examination, electrocardiogram, pulmonary function test (Forced Expiratory Volume in 1 second ≥ 80% of the predicted normal value and Forced Expiratory Volume in 1 second/ Forced Vital Capacity ≥ 70%).
  • Clinical laboratory values within the laboratory stated normal range; if not within this range, they must be without any clinical significance according to the Investigator.
  • Subjects who never smoked.
  • Women of childbearing potential (WOCBP) may be enrolled if they practice a method of birth control with a reliability of at least 90% and agree to continue doing so throughout the treatment period (e.g. condom, intrauterine device or hormonal contraception).
  • Any female subject with childbearing potential has a negative pregnancy test at Screening visit and prior to dosing at each treatment period.
  • Reliable subjects who are willing to be available for the duration of the clinical study and willing to comply with clinical study procedures.
  • Subjects who have the ability to understand the requirements of the clinical study.

Exclusion criteria

  • Any clinically important abnormality identified at the screening medical assessment (physical examination/medical history) or clinically relevant laboratory abnormalities.
  • Clinically significant history or presence of pulmonary malformations, chronic bronchitis, asthma, emphysema, cystic fibrosis or any other pulmonary disease
  • History or presence of pulmonary tuberculosis.
  • Viral or bacterial upper or lower respiratory tract infection, or sinus or middle ear infection, within 4 weeks prior to the screening visit.
  • Untreated oral candidiasis.
  • History or presence of prolonged QTc interval (> 450 ms), or any other clinically significant electrocardiogram abnormalities as judged by the Investigator based on 12-lead electrocardiogram recordings at Screening Visit.
  • History or presence of malignancy of any system organ class (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years prior to Screening Visit, regardless of whether there is no evidence of local recurrence or metastases.
  • Eye disorders, especially glaucoma, or a family history of glaucoma.
  • History of alcohol or drug abuse.
  • Inability to abstain from alcohol consumption for the duration of study period.
  • Immunosuppressive treatment, including topical and systemic corticosteroids (e.g., oral, parenteral, ocular, nasal or inhaled), within 4 weeks before Screening Visit.
  • Use of prescription or non-prescription drugs, except for simple analgesics (e.g. paracetamol) and hormonal contraception for women, including vitamins, herbal and dietary supplements (including St John's Wort [Hypericum]) within 7 days (or 2 weeks if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) before the Screening Visit.
  • Pregnant or breastfeeding female subjects.
  • History of hypersensitivity or existing contraindication to budesonide or any other study medication ingredients.
  • Blood or plasma donation within 4 weeks prior to Screening Visit.
  • Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the subject in case of participation in the clinical study.
  • History or presence of any other clinically relevant disease of any major system organ class (e.g. cardiovascular, pulmonary, renal, hepatic, gastrointestinal, reproductive, endocrinological including any type of Diabetes mellitus, neurological, psychiatric or orthopedic disease) as judged by the Investigator.
  • COVID-19, Hepatitis B and C and HIV positive tests
  • Any COVID-19 vaccine within 2 weeks prior to the first dose of study drugs, and during the entire study participation including 2 weeks after the last dose of study drug.
  • Subjects who participated in an investigational study within the 12 weeks prior to the start of the study

Treatment and study plan

Budesonide Inhalant Product

Drug

Single-dose of budesonide solution administered by nebulization.

Other names: Budesonide solution administered by nebulization

Primary outcomes

  1. Assessment of pharmacokinetics (Cmax) of budesonide through analysis of blood samples

    Time frame: Day 1 (predose) and at 2', 5', 10', 15', 20', 30', 45', 60', 90', 120', 180', 240', 360', 10h, 18h and 24h postdose

    Blood samples will be collected from each subject using an indwelling intravenous catheter.

    In total 17 blood samples for PK assessments over 24 hours will be collected.

  2. Assessment of pharmacokinetics (Tmax) of budesonide through analysis of blood samples

    Time frame: Day 1 (predose) and at 2', 5', 10', 15', 20', 30', 45', 60', 90', 120', 180', 240', 360', 10h, 18h and 24h postdose

    Blood samples will be collected from each subject using an indwelling intravenous catheter.

    In total 17 blood samples for PK assessments over 24 hours will be collected.

  3. Assessment of pharmacokinetics (AUC) of budesonide through analysis of blood samples

    Time frame: Day 1 (predose) and at 2', 5', 10', 15', 20', 30', 45', 60', 90', 120', 180', 240', 360', 10h, 18h and 24h postdose

    Blood samples will be collected from each subject using an indwelling intravenous catheter.

    In total 17 blood samples for PK assessments over 24 hours will be collected.

  4. Assessment of the safety through to incidence of Adverse Events of AQ001S inhalation solution

    Time frame: From baseline up to 17 days after first study drug intake

    Incidence of treatment-related adverse events (AE), including acute bronchospasm

  5. Assessment of the general tolerability through to vital signs (blood pressure: systolic and diastolic blood pressure) of AQ001S inhalation solution

    Time frame: From baseline up to 17 days after first study drug intake

    Vital signs assessment through blood pressure (systolic and diastolic blood pressure)

  6. Assessment of the general tolerability through to vital signs (pulse rate) of AQ001S inhalation solution

    Time frame: From baseline up to 17 days after first study drug intake

    Vital signs assessment through pulse rate

  7. Assessment of the general tolerability through to vital signs (respiratory rate) of AQ001S inhalation solution

    Time frame: From baseline up to 17 days after first study drug intake

    Vital signs assessment through respiratory rate

  8. Assessment of the general tolerability through to ECG (PR interval duration)

    Time frame: From baseline up to 17 days after first study drug intake

    ECG assessment through to PR interval duration

  9. Assessment of the general tolerability through to ECG (heart rhythm) of AQ001S inhalation solution

    Time frame: From baseline up to 17 days after first study drug intake

    ECG assessment through to heart rhythm

  10. Assessment of the general tolerability through to ECG (QRS interval duration) of AQ001S inhalation solution

    Time frame: From baseline up to 17 days after first study drug intake

    ECG assessment through to QRS interval duration

  11. Assessment of the general tolerability through to ECG (Corrected QT interval (QTc)) of AQ001S inhalation solution

    Time frame: From baseline up to 17 days after first study drug intake

    ECG assessment through to Corrected QT interval

  12. Assessment of the general tolerability through to ECG (QT interval duration) of AQ001S inhalation solution

    Time frame: From baseline up to 17 days after first study drug intake

    ECG assessment through to QT interval duration

  13. Assessment of the general tolerability through to physical examination

    Time frame: From baseline up to 17 days after first study drug intake

    General tolerability through the rate of patients with observed abnormalities in the following organic systems: general appearance, head and neck (incl. oropharyngeal examination), skin, respiratory system, cardiovascular system, abdomen, urogenital system, nervous system, ear, eyes and nose, musculoskeletal system

  14. Assessment of the local tolerability through to increased bronchial irritability of AQ001S inhalation solution

    Time frame: From baseline up to 17 days after first study drug intake

    Incidence of Increased bronchial irritability

  15. Assessment of the local tolerability through to paradoxical bronchospasm of AQ001S inhalation solution

    Time frame: From baseline up to 17 days after first study drug intake

    Incidence of paradoxical bronchospasm

  16. Assessment of the local tolerability through to oropharyngeal examination ((e.g. vocal cord myopathy, fungal infection) of AQ001S inhalation solution

    Time frame: From baseline up to 17 days after first study drug intake

    Incidence of oropharyngeal examination ((e.g. vocal cord myopathy, fungal infection)

Sponsors and collaborators

Lead sponsor

Aquilon Pharmaceuticals S.A.

Industry

Registry information

Official study title

A Randomized, Open Label, Single-center, Single-dose, Four-period Crossover Clinical Trial to Assess the PK Profile and Safety of Budesonide Inhalation Solution AQ001S Compared to Budesonide Inhalation Suspension in Healthy Volunteers

Acronym: BORA

Important dates

Study start
2021
Primary completion
2021
Study completion
2022
First posted
Dec 8, 2021
Registry last updated
Nov 3, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.